Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0767 in Patients With Metabolic Syndrome and Dyslipidemia
NCT00703690Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2002
- Primary completion
- Dec 2003
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-767 in metabolic syndrome and dyslipidemia (5 arms), sponsored by Merck & Co. Primary endpoint: Fasting Triglyceride Level at 12 weeks. Started Jan 2002; status: terminated.
02
Drugs
MK-767
03
Conditions
metabolic syndromedyslipidemia
Beyond the preview
Go deeper on NCT00703690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00703690.